Targeted degradation of membrane and extracellular proteins with LYTACs
Y Li, Y Yang, R Zhang, R Ge, S Xie - Acta Pharmacologica Sinica, 2024 - nature.com
Targeted protein degradation technology has gained substantial momentum over the past
two decades as a revolutionary strategy for eliminating pathogenic proteins that are …
two decades as a revolutionary strategy for eliminating pathogenic proteins that are …
DNA Nanotechnology for Application in Targeted Protein Degradation
Y Xiao, X Guo, W Zhang, L Ma… - ACS Biomaterials Science …, 2024 - ACS Publications
DNA is a kind of flexible and versatile biomaterial for constructing nanostructures and
nanodevices. Due to high biocompatibility and programmability and easy modification and …
nanodevices. Due to high biocompatibility and programmability and easy modification and …
Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis
P Zhou, S Zhang, L Li, R Zhang, G Guo, Y Zhang… - …, 2024 - pmc.ncbi.nlm.nih.gov
Rationale: Neovascular ocular diseases (NODs) represent the leading cause of visual
impairment globally. Despite significant advances in anti-angiogenic therapies targeting …
impairment globally. Despite significant advances in anti-angiogenic therapies targeting …
[HTML][HTML] Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis
M Yang, Y Mu, X Yu, D Gao, W Zhang, Y Li, J Liu… - Biomedicine & …, 2024 - Elsevier
During tumor development, the tumor itself must continuously generate new blood vessels to
meet their growth needs while also allowing for tumor invasion and metastasis. One of the …
meet their growth needs while also allowing for tumor invasion and metastasis. One of the …
Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics
W Zhao, Y Jiang, X Li, H Wang - Wiley Interdisciplinary Reviews …, 2024 - Wiley Online Library
Targeted protein degradation (TPD) represents an innovative therapeutic strategy that has
garnered considerable attention from both academic and industrial sectors due to its …
garnered considerable attention from both academic and industrial sectors due to its …
Update on the Development of TGR5 Agonists for Human Diseases
The G protein-coupled bile acid receptor 1 (GPBAR1) or TGR5 is widely distributed across
organs, including the small intestine, stomach, liver, spleen, and gallbladder. Many studies …
organs, including the small intestine, stomach, liver, spleen, and gallbladder. Many studies …
Fundamental Principles of Rational Design and Optimization of the Protac
X Cao, Y Li, Z Qu, L Jiang, H Chen, J Qu, J Tan… - Available at SSRN … - papers.ssrn.com
Even though the clinical success of lenalidomide shows the therapeutic potential of
PROTAC and extensive research was making efforts into this field, there was still limited …
PROTAC and extensive research was making efforts into this field, there was still limited …